[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019

May 2019 | 1115 pages | ID: DC33BCC89E3EN
GlobalData

US$ 2,500.00

Email Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019

SUMMARY

GlobalData's clinical trial report, “Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019' provides an overview of Diffuse Large B-Cell Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

REASONS TO BUY
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma
May 08, 2019: Innovative Cellular Therapeutics announces data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
May 07, 2019: Two clinical studies with IBI301, a biosimilar candidate to rituximab, met primary endpoints
May 03, 2019: IMV to provide updated data from phase 2 study evaluating DPX-Survivac in combination with Merck's Keytruda in DLBCL
May 01, 2019: Mixed results for new lymphoma therapy
Apr 10, 2019: Nordic Nanovector: safety review committee approves advancing to final dosing regimen in phase 1 trial of Betalutin in DLBCL
Apr 10, 2019: First patient enrolled in clinical trial for TREAKISYM rapid infusion liquid formulation
Apr 08, 2019: Completion of patient enrollment in phase 3 clinical trial of the anti-cancer drug Treakisym in relapsed/refractory diffuse large B-cell lymphoma
Apr 02, 2019: Kura Oncology identifies farnesylated proteins associated with CXCL12 expression, potential biomarker of clinical benefit from Tipifarnib in lymphoma indications
Mar 29, 2019: Kymera Therapeutics to present new preclinical data for its first-in-class oral IRAK4 degrader in MYD88-mutant lymphoma at late-breaking session of the American Association for Cancer Research Annual Meeting
Mar 28, 2019: Molecular Templates announces initiation of phase II monotherapy study of MT-3724 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients
Mar 07, 2019: MorphoSys provides updates on L-MIND and B-MIND clinical trials of MOR208 in relapsed/refractory DLBCL
Mar 05, 2019: EMA recommends Phase III study for VAL001
Feb 20, 2019: ADC Therapeutics announces first patient dosed in phase I clinical trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source

LIST OF TABLES

Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019*
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*

LIST OF FIGURES

Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019*
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
GlobalData Methodology

COMPANIES MENTIONED

F. Hoffmann-La Roche Ltd
Bristol-Myers Squibb Co
Johnson & Johnson
Amgen Inc
Novartis AG
AstraZeneca Plc
AbbVie Inc
Merck & Co Inc
Gilead Sciences Inc
Takeda Pharmaceutical Co Ltd


More Publications